

# **Basic and Therapeutic Aspects of Perinatal Pharmacology**

**Editors**

**P. L. Morselli, S. Garattini**

**F. Sereni**



MONOGRAPHS OF THE MARIO NEGRI INSTITUTE  
FOR PHARMACOLOGICAL RESEARCH, MILAN

---

# Basic and Therapeutic Aspects of Perinatal Pharmacology

Editors

P. L. Morselli, M.D.  
*Head, Clinical Pharmacology  
Department  
Mario Negri Institute for  
Pharmacological Research  
Milan, Italy*

S. Garattini, M.D.  
*Director, Mario Negri Institute  
for Pharmacological Research  
Milan, Italy*

F. Sereni, M.D.  
*Professor and Chairman,  
Department of Child Health  
University of Milan School of  
Medicine  
Milan, Italy*

Raven Press ■ New York

*Distributed in the Eastern Hemisphere by*

North-Holland Publishing Company ■ Amsterdam

---

© 1975 by Raven Press Books, Ltd. All rights reserved. This book is protected by copyright. No part of it may be duplicated or reproduced in any manner without written permission from the publisher.

Made in the United States of America

International Standard Book Number 0-89004-016-8  
Library of Congress Catalog Card Number 74-21981

*ISBN outside North and South America  
only: 0-7204-7541-4*

---

**BASIC AND THERAPEUTIC ASPECTS OF  
PERINATAL PHARMACOLOGY**

# MONOGRAPHS OF THE MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH, MILAN

---

SERIES EDITOR: SILVIO GARATTINI

Amphetamines and Related Compounds

*Edited by E. Costa and S. Garattini*

Basic and Therapeutic Aspects of Perinatal Pharmacology

*Edited by P. L. Morselli, S. Garattini, and F. Sereni*

The Benzodiazepines

*Edited by S. Garattini, E. Mussini, and L. O. Randall*

Chemotherapy of Cancer Dissemination and Metastasis

*Edited by S. Garattini and G. Franchi*

Drug Interactions

*Edited by P. L. Morselli, S. Garattini, and S. N. Cohen*

Insolubilized Enzymes

*Edited by M. Salmons, C. Saronio, and S. Garattini*

Isolated Liver Perfusion and Its Applications

*Edited by I. Bartošek, A. Guaitani, and L. L. Miller*

Mass Spectrometry in Biochemistry and Medicine

*Edited by A. Frigerio and N. Castagnoli, Jr.*

## PREFACE

It has become increasingly evident in recent years that extrapolation of pharmacologic data from adults to infants, corrected only for differences in size, is frequently meaningless and occasionally dangerous.

The importance of the *qualitative* differences between infants and adults has been shown by many studies. These differences are particularly significant in regard to specific pharmacologic processes including the absorption, distribution, biotransformation, and excretion of drugs. Drug protein binding is also affected by age. Sensitivity of newborn organisms to certain drugs can vary considerably from that of the adult.

Furthermore, the transfer of drugs or their metabolites, or both, through the placenta to the fetus or through maternal milk to the breast-fed infant is a problem unique to perinatal pharmacology. Very little is known about the long-term effects that such transfer or direct drug administration has on the development of the infant's various organs, resulting in physical and behavioral changes.

Most of these problems can be solved only through a concerted multidisciplinary effort, involving close cooperation and an exchange of information among scientists engaged in both basic and clinical research.

It is hoped that this volume, based on a symposium held in Milan on June 17 to 19, 1974, that brought together distinguished scientists from many countries and many disciplines, will contribute to this effort.

S. Garattini  
*Director, Mario Negri Institute for  
Pharmacological Research*

## CONTRIBUTORS\*

### **\*Else Ackermann**

*Abteilung für Klinische Pharmakologie  
Medizinische Akademie "Carl Gustav  
Carus"*

*Fiedlerstrasse 27*

*8019 Dresden, German Democratic  
Republic*

### **\*M. W. Anders**

*Departments of Pharmacology and Pedi-  
atrics*

*Division of Clinical Pharmacology*

*University of Minnesota—Minneapolis  
Medical School*

*Minneapolis, Minnesota 55455*

### **\*B. M. Assael**

*Laboratory of Clinical Pharmacology  
Istituto di Ricerche Farmacologiche*

*"Mario Negri"*

*Via Eritrea, 62*

*20157 Milan, Italy*

### **Daniel L. Azarnoff**

*See R. E. Kauffman*

### **John R. Bend**

*See J. R. Fouts*

### **P. Bergheim**

*See K. J. Netter*

### **\*Robert C. Boerth**

*Division of Pediatric Cardiology*

*Vanderbilt University Medical Center*

*Nashville, Tennessee 37232*

### **Robert C. Borer, Jr.**

*See D. W. Roloff*

### **\*Lars O. Boréus**

*Departments of Clinical Pharmacology  
and Pediatrics*

*Karolinska Hospital*

*Stockholm, Sweden*

### **Milas Boublik**

*Roche Institute of Molecular Biology*

*Nutley, New Jersey 07110*

### **\*Yvonne Brackbill**

*Departments of Obstetrics and Gynecol-  
ogy, and Pediatrics*

*Georgetown University School of Medi-  
cine*

*Washington, D.C. 20007*

### **John J. Burns**

*See W. Kuenzig*

### **\*Richard Butcher**

*Departments of Research Pediatrics and  
Psychology*

*Children's Hospital Research Foundation*

*University of Cincinnati College of Medi-  
cine*

*Cincinnati, Ohio 45229*

### **\*J. Capdevila**

*Departments of Forensic Medicine and  
Clinical Pharmacology*

*Huddinge Hospital*

*Karolinska Institutet*

*S-104 01 Stockholm 60, Sweden*

### **Leland W. K. Chung**

*See A. H. Neims*

### **James F. Connaughton**

*See L. Finnegan*

### **A. H. Conney**

*See W. Levin*

### **M. J. Cooper**

*See M. W. Anders*

### **Theodora R. Devereux**

*See J. R. Fouts*

---

\* Names preceded by an asterisk are those of first authors.

**John P. Emich**

See L. Finnegan

**\*Loretta Finnegan**

Department of Pediatrics  
University of Pennsylvania School of  
Medicine  
3400 Spruce Street  
and Philadelphia General Hospital  
700 Civic Center Boulevard  
Philadelphia, Pennsylvania 19104

**\*Mieczyslaw Finster**

Columbia University College of Physicians  
and Surgeons  
622 West 168th Street  
New York, New York 10032

**\*James R. Fouts**

Pharmacology Branch  
National Institute of Environmental  
Health Sciences  
National Institutes of Health  
Research Triangle Park, North Carolina  
27709

**J. Frohlich**

See P. Hahn

**\*E. Gladtko**

The Children's Hospital  
University of Cologne  
Cologne, German Federal Republic

**\*Leonard Glass**

Department of Pediatrics  
Jewish Hospital and Medical Center of  
Brooklyn  
Brooklyn, New York 11238

**R. Gomeni**

See B. M. Assael

**\*Peter Hahn**

Departments of Pediatrics, and Obstetrics  
and Gynecology  
Center for Developmental Medicine  
University of British Columbia  
Vancouver, British Columbia, Canada

**\*Raymond D. Harbison**

Department of Pharmacology and Center  
in Toxicology  
Vanderbilt University School of Medicine  
Nashville, Tennessee 37232

**S. Hartz**

See D. Slone

**Alois R. Hastreiter**

University of Illinois  
Chicago, Illinois 60612

**Karen Hawver**

See R. Butcher

**G. Heimann**

See E. Gladtko

**O. P. Heinonen**

See D. Slone

**\*Michael A. Heymann**

Department of Pediatrics  
Cardiovascular Research Institute  
University of California School of Medi-  
cine  
San Francisco, California 94143

**\*Charles Hoppell**

Department of Clinical Pharmacology  
Karolinska Institutet  
Huddinge University Hospital  
S-141 86 Huddinge, Sweden

**William F. Howatt**

See D. W. Roloff

**\*Costas Ioannides**

Department of Biochemistry  
University of Surrey  
Guildford, Surrey, England

**Birgitta Jalling**

See L. O. Boréus

**Margaret O. James**

See J. R. Fouts

**P. Jouppila**

See O. Pelkonen



**\*Mont R. Juchau**

Department of Pharmacology  
University of Washington School of Medicine SJ-30  
Seattle, Washington 98195

**Nils Källberg**

See L. O. Boréus

**Jerome J. Kamm**

See W. Kuenzig

**William P. Kanto, Jr.**

See D. W. Roloff

**Niilo T. Kärki**

See O. Pelkonen

**\*Ralph E. Kauffman**

Departments of Pediatrics, Medicine, and Pharmacology  
Clinical Pharmacology-Toxicology Center  
University of Kansas Medical Center  
Kansas City, Kansas 66103

**Kathy Kazmaier**

See R. Butcher

**L. Kirby**

See P. Hahn

**U. Kleeberg**

See W. Klinger

**\*W. Klinger**

Institute for Pharmacology and Toxicology  
Holzmarkt  
69 Jena, German Democratic Republic

**P. Korhonen**

See O. Pelkonen

**\*Joseph Krasner**

Department of Pediatrics  
State University of New York at Buffalo,  
School of Medicine  
Children's Hospital  
219 Bryant Street  
Buffalo, New York 14222

**Richard W. Krasula**

University of Illinois  
Chicago, Illinois 60612

**\*Béatrice Krauer**

Thiersteinerrain 90  
4059 Basel, Switzerland

**\*Norman Kretchmer**

National Institute of Child Health and Human Development  
Bethesda, Maryland 20014

**Reuben Kron**

See L. Finnegan

**\*Wolfgang Kuenzig**

Research Division  
Hoffmann-La Roche, Inc.  
Nutley, New Jersey 07110

**R. Kuntzman**

See W. Levin

**\*W. Levin**

Department of Biochemistry and Drug Metabolism  
Hoffmann-La Roche, Inc.  
Nutley, New Jersey 07110

**Sidney Levitsky**

University of Illinois  
Chicago, Illinois 60612

**\*Gerhard Levy**

Department of Pharmaceutics  
State University of New York at Buffalo,  
School of Pharmacy  
Buffalo, New York 14214

**H. Lübke**

See W. Klinger

**M. Mandelli**

Department of Child Health  
Faculty of Medicine  
University of Milan  
Milan, Italy

**A. Marini**

*Department of Obstetrics and Gynecology  
Division of Neonatology  
Faculty of Medicine  
University of Milan  
Milan, Italy*

**\*Giacomo Meschia**

*University of Colorado Medical Center  
4200 East Ninth Avenue  
Denver, Colorado 80220*

**\*Bernard L. Mirkin**

*See M. W. Anders*

**Paolo Lucio Morselli**

*See B. M. Assael*

**D. Müller**

*See W. Klinger*

**\*Daniel W. Nebert**

*Section on Developmental Pharmacology  
Laboratory of Biomedical Sciences  
National Institute of Child Health and  
Human Development  
Bethesda, Maryland 20014*

**\*Allen H. Neims**

*Roche Developmental Pharmacology Unit  
Departments of Pharmacology and Thera-  
peutics, and Pediatrics  
Montreal Children's Hospital Research In-  
stitute  
McGill University  
Montreal, Quebec, Canada*

**\*K. J. Netter**

*Department of Pharmacology  
University of Mainz  
D 65 Mainz, German Federal Republic*

**\*Franz Oesch**

*Department of Pharmacology  
Biozentrum of the University of Basel  
Klingelberstrasse 70  
CH-4056 Basel, Switzerland*

**S. Orrenius**

*See J. Capdevila*

**\*Marcello Orzalesi**

*Clicina Pediatrica dell'Università  
Viale Regina Elena, 324  
Rome, Italy*

**Dennis V. Parke**

*See C. Ioannides*

**\*Olavi Pelkonen**

*Departments of Pharmacology, Microbiol-  
ogy, and Obstetrics and Gynecology  
University of Oulu  
SF-90220 Oulu, 22, Finland*

**N. Principi**

*See B. M. Assael*

**B. V. Rama Sastry**

*See R. D. Harbison*

**Anders Rane**

*See J. Capdevila*

**F. Reichenbach**

*See W. Klinger*

**H. Rein**

*See W. Klinger*

**Klaus Richter**

*See E. Ackermann*

**T. F. Rolewicz**

*See M. W. Anders*

**\*Dietrich W. Roloff**

*Department of Pediatrics  
University of Michigan Medical Center  
Ann Arbor, Michigan 48104*

**Abraham M. Rudolph**

*See M. A. Heymann*

**D. Ryan**

*See W. Levin*

**Paul H. Sato**

*See V. G. Zannoni*

**William Scott**

See R. Butcher

**\*Fabio Sereni**

*Department of Child Health  
Faculty of Medicine  
University of Milan  
Milan, Italy*

**S. Shapiro**

See D. Slone

**Folke Sjöqvist**

See C. Hoppel

**\*D. Slone**

*Boston University Medical Center  
400 Totten Pond Road  
Waltham, Massachusetts 02154*

**\*Lester F. Soyka**

*Department of Pharmacology  
University of Vermont College of Medicine  
Burlington, Vermont 05401*

**\*Leo Stern**

*Section on Human Growth and Development, Brown University Program in Medicine, and Providence Lying-In-Hospital  
50 Maude Street  
Providence, Rhode Island 02908*

**Kari Teramo**

See M. A. Heymann

**H. Thor**

See J. Capdevila

**Gianni Tognoni**

*Drug Information System Laboratory of Clinical Pharmacology  
Istituto Di Ricerche Farmacologiche "Mario Negri"  
Via Eritrea, 62  
20157 Milan, Italy*

**\*Vittorio Tomasi**

*Institute of General Physiology  
University of Ferrara  
Ferrara, Italy*

**\*H. Uehleke**

*Institute of Pharmacology  
University of Tübingen  
74 Tübingen, German Federal Republic*

**\*Garry R. Van Petten**

*Division of Pharmacology and Therapeutics  
Faculty of Medicine  
University of Calgary  
Calgary, Alberta T2N 1N4, Canada*

**U. Visconti**

*Department of Child Health  
Faculty of Medicine  
University of Milan  
Milan, Italy*

**Margaret Warner**

See A. H. Neims

**T. Werner**

See H. Uehleke

**\*John T. Wilson**

*Departments of Pediatrics and Pharmacology  
Division of Pediatric Clinical Pharmacology  
Vanderbilt University School of Medicine  
Nashville, Tennessee 37232*

**Sumner J. Yaffe**

See J. Krasner

**Ho Yu Yang**

See A. H. Neims

**\*Vincent G. Zannoni**

*Department of Pharmacology  
New York University School of Medicine  
550 First Avenue  
New York, New York 10016*

## CONTENTS

- 1 Perinatal Pharmacology: An Introduction  
*Norman Kretchmer*

### PROBLEMS OF DRUG THERAPY IN THE NEWBORN

- 7 Drug Therapy in the Perinatal Period  
*Leo Stern*
- 13 Problems of Drug Therapy in the Newborn Period  
*Marcello Orzalesi*
- 21 Psychophysiological Measures of Pharmacological Toxicity in Infants: Perinatal and Postnatal Effects  
*Yvonne Brackbill*

### PLACENTAL TRANSFER OF DRUGS AND EFFECTS ON THE FETUS AND THE NEWBORN

- 29 Mixed-Function Oxidation in the Human Placenta  
*M. R. Juchau*
- 39 Some Characteristics of Human Placental Cytochrome P-450  
*K. J. Netter and P. Bergheim*
- 53 Transplacental Control of Epoxide-Forming and Inactivating Enzymes of Rat Fetal Liver by Clinically Used Drugs and by Environmental Chemicals  
*Franz Oesch*
- 65 Placental Transfer and Fetal Metabolism of Drugs  
*Olavi Pelkonen, Pekka Korhonen, Pentti Jouppila, and Niilo T. Kärki*
- 75 Placental Transfer and Fetal Urinary Excretion of Gentamicin—Comparison Between an Animal Model and the Human Fetus  
*Ralph E. Kauffman, Daniel L. Azarnoff, and John A. Morris*
- 83 Fetal Cardiovascular Effects of Maternally Administered Tricyclic Antidepressants  
*G. R. Van Petten*
- 89 Effect of Estrogens on Uterine Blood Flow  
*Giacomo Meschia*

- 97      Effects of Local Anesthetic Agents on Fetal Circulation  
*Michael A. Heymann, Kari A. W. Teramo, and Abraham M. Rudolph*
- 107     Proposed Role of the Placental Cholinergic System in the Regulation of Fetal Growth and Development  
*Raymond D. Harbison, Joseph Olubadewo, Chandradhar Dwivedi, and B. V. Rama Sastry*

### EFFECTS OF NARCOTICS ON THE FETUS AND THE NEWBORN

- 121     The Effect of Long-Term Maternal Morphine Administration on the Growth and Lung Development of Fetal Rabbits  
*Dietrich W. Roloff, William F. Howatt, William P. Kanto, and Robert C. Borer*
- 131     Effects of Narcotics on the Fetus  
*Leonard Glass*
- 139     A Scoring System for Evaluation and Treatment of the Neonatal Abstinence Syndrome: A New Clinical and Research Tool  
*Loretta P. Finnegan, Reuben E. Kron, James F. Connaughton, Jr., and John P. Emich, Jr.*

### DRUG TOXICITY AND EFFECTS IN THE PERINATAL PERIOD

- 155     Pharmacogenetic Aspects of Drug Toxicity and Teratogenesis in the Newborn  
*Joseph R. Robinson, James S. Felton, Snorri S. Thorgeirsson, and Daniel W. Nebert*
- 171     Postnatal Behavioral Effects from Prenatal Exposure to Teratogens  
*Richard E. Butcher, Karen Hawver, Kathy Kazmaier, and William Scott*
- 177     Relative Deficiency in the Elimination of Hexachlorophene by Neonatal Rodents  
*A. H. Neims, M. Warner, G. Yang, B. Hales, L. W. K. Chung, and D. S. R. East*
- 191     Decreased Sensitivity of Newborn Myocardium to the Positive Inotropic Effects of Ouabain  
*Robert C. Boerth*

**DEVELOPMENTAL ASPECTS**

- 201 Developmental Aspects of the Control of Cyclic-AMP Levels in Rat Liver  
*V. Tomasi, A. Trevisani, O. Barnabei, and F. Sereni*
- 215 Hormonal Regulation of Enzyme Activities in Rat and Human Fetal Tissues  
*Peter Hahn, L. Kirby, and J. Frohlich*
- 229 Toxication-Detoxication Systems in Hepatic and Extrahepatic Tissues in the Perinatal Period  
*John R. Bend, Margaret O. James, Theodora R. Devereux, and James R. Fouts*
- 245 Development of the Hepatic Microsomal Drug-Metabolizing Enzymes in the Ferret  
*Costas Ioannides and Dennis V. Parke*
- 255 Developmental Aspects of the Microsomal Electron-Transport Chain in the Rat  
*W. Klinger, D. Müller, F. Reichenbach, U. Kleeberg, H. Lübke, and H. Rein*
- 265 Age and Sex Differences in the Turnover of Rat Liver Cytochrome P-450: The Role of Neonatal Imprinting  
*W. Levin and D. Ryan*
- 277 Postnatal Development of Halothane and Other Haloalkane Metabolism and Covalent Binding in Rat Liver Microsomes  
*H. Uehleke and T. Werner*

**DRUG INTERACTIONS IN THE PERINATAL PERIOD**

- 289 The Effect of Phenobarbital on the Microsomal Mixed-Function Oxidase System and Hepatic Ultrastructure in the Perinatal Guinea Pig  
*W. Kuenzig, J. J. Kamm, M. Boublik, and J. J. Burns*
- 301 Effects of Ascorbic Acid on Drug Metabolism in the Perinatal Guinea Pig  
*Vincent G. Zannoni and Paul H. Sato*

**VARIOUS ASPECTS OF DRUG KINETICS IN THE FETUS AND THE NEWBORN**

- 311 Diazepam Metabolism in Human Fetal Liver Microsomes  
*Else Ackermann and Klaus Richter*

- 319 Salicylate Pharmacokinetics in the Human Neonate  
*Gerhard Levy*
- 331 Clinical Pharmacology of Phenobarbital in the Neonatal Period  
*Lars O. Boréus, Birgitta Jalling, and Nils Kållberg*
- 341 Kinetics of Phenytoin and Carbamazepine in the Newborn  
*Charles Hoppel, Anders Rane, and Folke Sjöqvist*
- 347 The Development of Diurnal Variation in Drug Kinetics in the Human Infant  
*Béatrice Krauer*
- 357 Drug-Protein Binding in the Neonate  
*Joseph Krasner and Sumner J. Yaffe*
- 367 Changes in Serum, Tissue, and Urinary Excretion of Digoxin in Children Undergoing Cardiopulmonary Bypass  
*Lester F. Soyka, Richard W. Krasula, Ruth Yanagi, Alois R. Hastreiter, and Sidney Levitsky*
- 377 Digoxin Pharmacokinetics During Human Development  
*P. L. Morselli, B. M. Assael, R. Gomeni, M. Mandelli, A. Marini, E. Reali, U. Visconti, and F. Sereni*
- 393 The Rate of Development of Elimination Functions in Kidney and Liver of Young Infants  
*E. Gladtko and G. Heimann*
- 405 Application of High-Pressure Liquid Chromatography in Pediatric Pharmacology: Pharmacokinetics of Cephalothin in Man  
*M. W. Anders, M. J. Cooper, T. F. Rolewicz, and B. L. Mirkin*
- ETHICAL AND PRACTICAL PROBLEMS OF  
CLINICAL TRIALS AND CLINICAL PRACTICE**
- 411 Pragmatic Assessment of Medicines Available for Young Children and Pregnant or Breast-Feeding Women  
*John T. Wilson*
- 423 Ethical and Methodological Challenges in Research in Perinatal Pharmacology  
*G. Tognoni, P. L. Morselli, and F. Sereni*
- 431 *Subject Index*

## Perinatal Pharmacology: An Introduction

Norman Kretchmer\*

*National Institute of Child Health and Human Development, National Institutes of Health, Bethesda,  
Maryland 20014*

Perinatal pharmacology as a subdivision of developmental pharmacology should include studies of that period of life before and shortly after birth. The goals of the field are similar to all of pharmacology: the examination of the adverse and therapeutic effects of pharmaceutical agents. This study should consist not only of these mission-oriented goals, but must also include a scholarly examination of basic physiologic and biochemical phenomena. Most important is that the realistic biologic responsibilities of perinatal pharmacology include the complex integrated physiologic unit consisting of mother, uterus, placenta, and fetus. All organs and organisms in this unit are at different stages of development, and the system truly presents a pharmacologic challenge. The neonate, although less complex physiologically, manifests a number of very special pharmacologic problems not encountered in the mature organism. It is deplorable that the overt appreciation of the general medical and legislative public for the special considerations of drug usage in mother and child required the clinical calamities of chloramphenicol, thalidomide, and other drugs. As with many startling events, there were derived benefits in knowledge and caution, intertwined with overt hysteria and restrictive action. However, the possibility for creative advance in this field is great, with an eventual benefit to mother and child.

I would like to consider a few aspects of perinatal pharmacology and particularly concentrate on (1) the general action of drugs in the perinatal environment; (2) some specific examples of these actions directly on metabolic and genetic systems, as well as interaction with other environmental factors, such as nutrients; and finally (3) the potentiality for future practical contributions of perinatal pharmacology to clinical medicine.

A drug, when administered, can act directly on a metabolic system and thereby stimulate or inhibit a set of reactions which result in a predetermined physiologic effect. The potentiality for a drug to be toxic is related to the perturbation of the physiology so severely that the individual demonstrates disease. This effect can either be direct or result from interference with other specific pathways, or by interaction with other agents. Also, it has been shown

---

\* Guggenheim Fellow in Human Development; On Leave, Department of Pediatrics, Stanford University Medical Center, Stanford, California 94305



that a number of agents, particularly steroids, phenobarbital, and thyroxin, exert their pharmacologic effect by determination of the rate of synthesis or degradation of an enzyme.

In the case of the fetus or infant, we encounter a system in the kinetic state of development where one metabolic time period of observation does not necessarily resemble the next. This kinetic biologic state makes perinatal biology a difficult but most exciting field. It is a biology of constant change, constituting a flow from immaturity to maturity.

The general cellular phenomena of proliferation and differentiation of cells is most prevalent in the immature organism, but continues throughout life in many specific organs. Proliferation is carried on by all cells sometime during their life span, and differentiation endows these cells with a specialness. All cells are not the same during proliferation; and although there must be some molecular degree of predetermination, there are basic distinctive biologic mechanisms of cell division which are shared by all proliferating cells. All differentiated cells are dissimilar, but they share some similar life-preserving processes. Both differentiation and proliferation are genetically controlled. The fetus or neonate not only differs from the adult in that the development of certain cells occurs at different stages, but also in the general functional aspects of the organisms that emanate from these major differences in cellular biology. The adult and the fetus are the same in that, regardless of their differences, their biology is appropriate to their particular environment and both have specific metabolic needs which are required for adaptation. In the case of the fetus or neonate, there is particular sensitivity to disruption of environment, and ability to adapt is fleeting since we are dealing with an exquisitely time-dependent system.

A number of these thoughts have been incorporated into reviews on teratology and perinatal medication (Pomerance and Yaffe, 1973). It has been clearly shown that some drugs or macromolecules (viruses) have specific deleterious actions on particular organ systems at certain distinct times during embryogenesis. The teratologic effect of a drug is dependent on its ability to cross the placenta and upon the specific period of development during which it is administered. A most fascinating example for me is the recent data that have accumulated regarding diphenylhydantoin.

Diphenylhydantoin (DPH) traverses the placenta with ease, and, as shown by Mirkin (1971) and others, the concentration in cord blood is approximately that found in maternal blood. There are a number of congenital malformations associated with anticonvulsant therapy, particularly those involving the palate (Hill, Horning, and Horning, 1973). Data from Hauser and Kurland (1975) indicate that in a total group of 284 children from 138 women with epilepsy, there were 141 children born from mothers who received one or more anticonvulsants. Of these 141, there were 10 or more with serious malformations; 5 had congenital cardiac malformation, 2 had cleft palate, and the remainder had a variety of anomalies. In contrast, there